These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33381657)

  • 1. The ovarian sensitivity index is predictive of live birth chances after IVF in infertile patients.
    Weghofer A; Barad DH; Darmon SK; Kushnir VA; Albertini DF; Gleicher N
    Hum Reprod Open; 2020; 2020(4):hoaa049. PubMed ID: 33381657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
    Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
    Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diminished ovarian reserve and poor response to stimulation in patients <38 years old: a quantitative but not qualitative reduction in performance.
    Morin SJ; Patounakis G; Juneau CR; Neal SA; Scott RT; Seli E
    Hum Reprod; 2018 Aug; 33(8):1489-1498. PubMed ID: 30010882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve.
    Romanski PA; Bortoletto P; Rosenwaks Z; Schattman GL
    Hum Reprod; 2020 Jul; 35(7):1630-1636. PubMed ID: 32544225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian response is associated with anogenital distance in patients undergoing controlled ovarian stimulation for IVF.
    Fabregues F; González-Foruria I; Peñarrubia J; Carmona F
    Hum Reprod; 2018 Sep; 33(9):1696-1704. PubMed ID: 30016431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative live birth rates in low-prognosis women.
    Leijdekkers JA; Eijkemans MJC; van Tilborg TC; Oudshoorn SC; van Golde RJT; Hoek A; Lambalk CB; de Bruin JP; Fleischer K; Mochtar MH; Kuchenbecker WKH; Laven JSE; Mol BWJ; Torrance HL; Broekmans FJM;
    Hum Reprod; 2019 Jun; 34(6):1030-1041. PubMed ID: 31125412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corifollitropin alfa followed by highly purified HMG versus recombinant FSH in young poor ovarian responders: a multicentre randomized controlled clinical trial.
    Drakopoulos P; Vuong TNL; Ho NAV; Vaiarelli A; Ho MT; Blockeel C; Camus M; Lam AT; van de Vijver A; Humaidan P; Tournaye H; Polyzos NP
    Hum Reprod; 2017 Nov; 32(11):2225-2233. PubMed ID: 29040589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oocyte matched follicular fluid anti-Müllerian hormone is an excellent predictor of live birth after fresh single embryo transfer.
    Ciepiela P; Dulęba AJ; Kario A; Chełstowski K; Branecka-Woźniak D; Kurzawa R
    Hum Reprod; 2019 Nov; 34(11):2244-2253. PubMed ID: 31725884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study.
    Barad DH; Albertini DF; Molinari E; Gleicher N
    Hum Reprod Open; 2022; 2022(3):hoac027. PubMed ID: 35795849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Live birth rates after modified natural cycle compared with high-dose FSH stimulation using GnRH antagonists in poor responders.
    Lainas TG; Sfontouris IA; Venetis CA; Lainas GT; Zorzovilis IZ; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2015 Oct; 30(10):2321-30. PubMed ID: 26307091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised controlled trial on the effect of clomiphene citrate and gonadotropin dose on ovarian response markers and IVF outcomes in poor responders.
    Moffat R; Hansali C; Schoetzau A; Ahler A; Gobrecht U; Beutler S; Raggi A; Sartorius G; De Geyter C
    Hum Reprod; 2021 Mar; 36(4):987-997. PubMed ID: 33367742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial of AMH-based individualized FSH dosing in a GnRH antagonist protocol for IVF.
    Friis Petersen J; Løkkegaard E; Andersen LF; Torp K; Egeberg A; Hedegaard L; Nysom D; Nyboe Andersen A
    Hum Reprod Open; 2019; 2019(1):hoz003. PubMed ID: 30895268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased versus standard gonadotrophin dosing in predicted poor responders of IVF: an open-label randomized controlled trial.
    Liu X; Wen W; Wang T; Tian L; Li N; Sun T; Wang T; Zhou H; Zhang N; Qu P; Mol BW; Li W; Shi J
    Hum Reprod; 2022 Jul; 37(8):1806-1815. PubMed ID: 35595197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 1: The predicted poor responder.
    van Tilborg TC; Torrance HL; Oudshoorn SC; Eijkemans MJC; Koks CAM; Verhoeve HR; Nap AW; Scheffer GJ; Manger AP; Schoot BC; Sluijmer AV; Verhoeff A; Groen H; Laven JSE; Mol BWJ; Broekmans FJM;
    Hum Reprod; 2017 Dec; 32(12):2496-2505. PubMed ID: 29121326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis.
    Bordewijk EM; Mol F; van der Veen F; Van Wely M
    Hum Reprod Open; 2019; 2019(3):hoz008. PubMed ID: 31206036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment.
    Peuranpää P; Hautamäki H; Halttunen-Nieminen M; Hydén-Granskog C; Tiitinen A
    Hum Reprod; 2020 Mar; 35(3):504-515. PubMed ID: 32219343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI.
    Mostinckx L; Goyens E; Mackens S; Roelens C; Boudry L; Uvin V; Segers I; Schoemans C; Drakopoulos P; Blockeel C; De Vos M
    Hum Reprod; 2024 Mar; 39(3):586-594. PubMed ID: 38177084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.